context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
The fair value of PSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of PSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. Earned PSUs as of year end 2024, 2023, and 2022 totaled 63,445 shares, 137,096 shares and 61,839 shares, respectively. Earned PSUs vest and are generally paid out following the conclusion of the applicable performance period upon approval by the Organization and Executive Compensation Committee of the company’s Board of Directors (the “Board”). PSUs related to 137,096 shares, 60,402 shares and 46,217 shares were paid out in 2024, 2023 and 2022, respectively. | text | 249.26 | perShareItemType | text: <entity> 249.26 </entity> <entity type> perShareItemType </entity type> <context> The fair value of PSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of PSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. Earned PSUs as of year end 2024, 2023, and 2022 totaled 63,445 shares, 137,096 shares and 61,839 shares, respectively. Earned PSUs vest and are generally paid out following the conclusion of the applicable performance period upon approval by the Organization and Executive Compensation Committee of the company’s Board of Directors (the “Board”). PSUs related to 137,096 shares, 60,402 shares and 46,217 shares were paid out in 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The fair value of PSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of PSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. Earned PSUs as of year end 2024, 2023, and 2022 totaled 63,445 shares, 137,096 shares and 61,839 shares, respectively. Earned PSUs vest and are generally paid out following the conclusion of the applicable performance period upon approval by the Organization and Executive Compensation Committee of the company’s Board of Directors (the “Board”). PSUs related to 137,096 shares, 60,402 shares and 46,217 shares were paid out in 2024, 2023 and 2022, respectively. | text | 211.67 | perShareItemType | text: <entity> 211.67 </entity> <entity type> perShareItemType </entity type> <context> The fair value of PSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of PSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. Earned PSUs as of year end 2024, 2023, and 2022 totaled 63,445 shares, 137,096 shares and 61,839 shares, respectively. Earned PSUs vest and are generally paid out following the conclusion of the applicable performance period upon approval by the Organization and Executive Compensation Committee of the company’s Board of Directors (the “Board”). PSUs related to 137,096 shares, 60,402 shares and 46,217 shares were paid out in 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The fair value of PSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of PSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. Earned PSUs as of year end 2024, 2023, and 2022 totaled 63,445 shares, 137,096 shares and 61,839 shares, respectively. Earned PSUs vest and are generally paid out following the conclusion of the applicable performance period upon approval by the Organization and Executive Compensation Committee of the company’s Board of Directors (the “Board”). PSUs related to 137,096 shares, 60,402 shares and 46,217 shares were paid out in 2024, 2023 and 2022, respectively. | text | 63445 | sharesItemType | text: <entity> 63445 </entity> <entity type> sharesItemType </entity type> <context> The fair value of PSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of PSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. Earned PSUs as of year end 2024, 2023, and 2022 totaled 63,445 shares, 137,096 shares and 61,839 shares, respectively. Earned PSUs vest and are generally paid out following the conclusion of the applicable performance period upon approval by the Organization and Executive Compensation Committee of the company’s Board of Directors (the “Board”). PSUs related to 137,096 shares, 60,402 shares and 46,217 shares were paid out in 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod |
The fair value of PSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of PSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. Earned PSUs as of year end 2024, 2023, and 2022 totaled 63,445 shares, 137,096 shares and 61,839 shares, respectively. Earned PSUs vest and are generally paid out following the conclusion of the applicable performance period upon approval by the Organization and Executive Compensation Committee of the company’s Board of Directors (the “Board”). PSUs related to 137,096 shares, 60,402 shares and 46,217 shares were paid out in 2024, 2023 and 2022, respectively. | text | 137096 | sharesItemType | text: <entity> 137096 </entity> <entity type> sharesItemType </entity type> <context> The fair value of PSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of PSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. Earned PSUs as of year end 2024, 2023, and 2022 totaled 63,445 shares, 137,096 shares and 61,839 shares, respectively. Earned PSUs vest and are generally paid out following the conclusion of the applicable performance period upon approval by the Organization and Executive Compensation Committee of the company’s Board of Directors (the “Board”). PSUs related to 137,096 shares, 60,402 shares and 46,217 shares were paid out in 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod |
The fair value of PSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of PSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. Earned PSUs as of year end 2024, 2023, and 2022 totaled 63,445 shares, 137,096 shares and 61,839 shares, respectively. Earned PSUs vest and are generally paid out following the conclusion of the applicable performance period upon approval by the Organization and Executive Compensation Committee of the company’s Board of Directors (the “Board”). PSUs related to 137,096 shares, 60,402 shares and 46,217 shares were paid out in 2024, 2023 and 2022, respectively. | text | 61839 | sharesItemType | text: <entity> 61839 </entity> <entity type> sharesItemType </entity type> <context> The fair value of PSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of PSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. Earned PSUs as of year end 2024, 2023, and 2022 totaled 63,445 shares, 137,096 shares and 61,839 shares, respectively. Earned PSUs vest and are generally paid out following the conclusion of the applicable performance period upon approval by the Organization and Executive Compensation Committee of the company’s Board of Directors (the “Board”). PSUs related to 137,096 shares, 60,402 shares and 46,217 shares were paid out in 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod |
As of 2024 year end, there was $ 14.2 million of unrecognized compensation cost related to non-vested PSUs that is expected to be recognized as a charge to earnings over a weighted-average period of 1.4 years. | text | 14.2 | monetaryItemType | text: <entity> 14.2 </entity> <entity type> monetaryItemType </entity type> <context> As of 2024 year end, there was $ 14.2 million of unrecognized compensation cost related to non-vested PSUs that is expected to be recognized as a charge to earnings over a weighted-average period of 1.4 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
The fair value of RSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of RSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. | text | 269.00 | perShareItemType | text: <entity> 269.00 </entity> <entity type> perShareItemType </entity type> <context> The fair value of RSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of RSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The fair value of RSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of RSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. | text | 249.26 | perShareItemType | text: <entity> 249.26 </entity> <entity type> perShareItemType </entity type> <context> The fair value of RSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of RSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The fair value of RSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of RSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. | text | 211.67 | perShareItemType | text: <entity> 211.67 </entity> <entity type> perShareItemType </entity type> <context> The fair value of RSUs is calculated using the market value of a share of Snap-on’s common stock on the date of grant and assumed forfeitures based on recent historical experience; in recent years, forfeitures have not been significant. The weighted-average grant date fair value of RSUs granted during 2024, 2023 and 2022, was $ 269.00 , $ 249.26 and $ 211.67 , respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
As of 2024 year end, there was $ 6.4 million of unrecognized compensation cost related to non-vested RSUs that is expected to be recognized as a charge to earnings over a weighted-average period of 1.1 years. | text | 6.4 | monetaryItemType | text: <entity> 6.4 </entity> <entity type> monetaryItemType </entity type> <context> As of 2024 year end, there was $ 6.4 million of unrecognized compensation cost related to non-vested RSUs that is expected to be recognized as a charge to earnings over a weighted-average period of 1.1 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. | text | 52.12 | perShareItemType | text: <entity> 52.12 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. | text | 48.85 | perShareItemType | text: <entity> 48.85 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. | text | 32.63 | perShareItemType | text: <entity> 32.63 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. | text | 2.3 | monetaryItemType | text: <entity> 2.3 </entity> <entity type> monetaryItemType </entity type> <context> The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> The weighted-average grant date fair value of stock-settled SARs granted was $ 52.12 in 2024, $ 48.85 in 2023 and $ 32.63 in 2022. The intrinsic value of stock-settled SARs exercised was $ 4.0 million in 2024, $ 5.3 million in 2023 and $ 1.7 million in 2022. The fair value of stock-settled SARs vested was $ 2.3 million in 2024, $ 1.9 million in 2023 and $ 2.0 million in 2022. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
As of 2024 year end, there was $ 3.5 million of unrecognized compensation cost related to non-vested stock-settled SARs that is expected to be recognized as a charge to earnings over a weighted-average period of 1.4 years. | text | 3.5 | monetaryItemType | text: <entity> 3.5 </entity> <entity type> monetaryItemType </entity type> <context> As of 2024 year end, there was $ 3.5 million of unrecognized compensation cost related to non-vested stock-settled SARs that is expected to be recognized as a charge to earnings over a weighted-average period of 1.4 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
The intrinsic value of cash-settled SARs exercised was zero in 2024, $ 0.4 million in 2023 and $ 0.6 million in 2022. The fair value of cash-settled SARs vested during 2024, 2023 and 2022 was $ 0.2 million, $ 0.1 million and $ 0.1 million, respectively. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> The intrinsic value of cash-settled SARs exercised was zero in 2024, $ 0.4 million in 2023 and $ 0.6 million in 2022. The fair value of cash-settled SARs vested during 2024, 2023 and 2022 was $ 0.2 million, $ 0.1 million and $ 0.1 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
The intrinsic value of cash-settled SARs exercised was zero in 2024, $ 0.4 million in 2023 and $ 0.6 million in 2022. The fair value of cash-settled SARs vested during 2024, 2023 and 2022 was $ 0.2 million, $ 0.1 million and $ 0.1 million, respectively. | text | 0.1 | monetaryItemType | text: <entity> 0.1 </entity> <entity type> monetaryItemType </entity type> <context> The intrinsic value of cash-settled SARs exercised was zero in 2024, $ 0.4 million in 2023 and $ 0.6 million in 2022. The fair value of cash-settled SARs vested during 2024, 2023 and 2022 was $ 0.2 million, $ 0.1 million and $ 0.1 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
As of 2024 year end, there was $ 0.3 million of unrecognized compensation cost related to non-vested cash-settled SARs that is expected to be recognized as a charge to earnings over a weighted-average period of 1.5 years. | text | 0.3 | monetaryItemType | text: <entity> 0.3 </entity> <entity type> monetaryItemType </entity type> <context> As of 2024 year end, there was $ 0.3 million of unrecognized compensation cost related to non-vested cash-settled SARs that is expected to be recognized as a charge to earnings over a weighted-average period of 1.5 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
The company awarded 5,391 shares, 5,760 shares and 6,525 shares of restricted stock to non-employee directors in 2024, 2023 and 2022, respectively. The fair value of the restricted stock awards is expensed over a one-year vesting period based on the fair value on the date of grant. All restrictions on the restricted stock awards generally lapse upon the earlier of the first anniversary of the grant date, the recipient’s death or disability or in the event of a change in control, as defined in the 2011 Plan. If termination of the recipient’s service occurs prior to the first anniversary of the grant date for any reason other than death or disability, the shares of restricted stock would be forfeited, unless otherwise determined by the Board. | text | 5391 | sharesItemType | text: <entity> 5391 </entity> <entity type> sharesItemType </entity type> <context> The company awarded 5,391 shares, 5,760 shares and 6,525 shares of restricted stock to non-employee directors in 2024, 2023 and 2022, respectively. The fair value of the restricted stock awards is expensed over a one-year vesting period based on the fair value on the date of grant. All restrictions on the restricted stock awards generally lapse upon the earlier of the first anniversary of the grant date, the recipient’s death or disability or in the event of a change in control, as defined in the 2011 Plan. If termination of the recipient’s service occurs prior to the first anniversary of the grant date for any reason other than death or disability, the shares of restricted stock would be forfeited, unless otherwise determined by the Board. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The company awarded 5,391 shares, 5,760 shares and 6,525 shares of restricted stock to non-employee directors in 2024, 2023 and 2022, respectively. The fair value of the restricted stock awards is expensed over a one-year vesting period based on the fair value on the date of grant. All restrictions on the restricted stock awards generally lapse upon the earlier of the first anniversary of the grant date, the recipient’s death or disability or in the event of a change in control, as defined in the 2011 Plan. If termination of the recipient’s service occurs prior to the first anniversary of the grant date for any reason other than death or disability, the shares of restricted stock would be forfeited, unless otherwise determined by the Board. | text | 5760 | sharesItemType | text: <entity> 5760 </entity> <entity type> sharesItemType </entity type> <context> The company awarded 5,391 shares, 5,760 shares and 6,525 shares of restricted stock to non-employee directors in 2024, 2023 and 2022, respectively. The fair value of the restricted stock awards is expensed over a one-year vesting period based on the fair value on the date of grant. All restrictions on the restricted stock awards generally lapse upon the earlier of the first anniversary of the grant date, the recipient’s death or disability or in the event of a change in control, as defined in the 2011 Plan. If termination of the recipient’s service occurs prior to the first anniversary of the grant date for any reason other than death or disability, the shares of restricted stock would be forfeited, unless otherwise determined by the Board. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The company awarded 5,391 shares, 5,760 shares and 6,525 shares of restricted stock to non-employee directors in 2024, 2023 and 2022, respectively. The fair value of the restricted stock awards is expensed over a one-year vesting period based on the fair value on the date of grant. All restrictions on the restricted stock awards generally lapse upon the earlier of the first anniversary of the grant date, the recipient’s death or disability or in the event of a change in control, as defined in the 2011 Plan. If termination of the recipient’s service occurs prior to the first anniversary of the grant date for any reason other than death or disability, the shares of restricted stock would be forfeited, unless otherwise determined by the Board. | text | 6525 | sharesItemType | text: <entity> 6525 </entity> <entity type> sharesItemType </entity type> <context> The company awarded 5,391 shares, 5,760 shares and 6,525 shares of restricted stock to non-employee directors in 2024, 2023 and 2022, respectively. The fair value of the restricted stock awards is expensed over a one-year vesting period based on the fair value on the date of grant. All restrictions on the restricted stock awards generally lapse upon the earlier of the first anniversary of the grant date, the recipient’s death or disability or in the event of a change in control, as defined in the 2011 Plan. If termination of the recipient’s service occurs prior to the first anniversary of the grant date for any reason other than death or disability, the shares of restricted stock would be forfeited, unless otherwise determined by the Board. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
Under the Directors’ 1993 Fee Plan, as amended, non-employee directors may elect to receive up to 100 % of their fees and retainer in shares of Snap-on’s common stock. Directors may elect to defer receipt of all or part of these shares. For 2024, 2023 and 2022, issuances under the Directors’ Fee Plan totaled 441 shares, 449 shares and 621 shares, respectively, of which 184 shares, 176 shares and 309 shares, respectively, were deferred. As of 2024 year end, shares reserved for issuance to directors under this plan totaled 194,840 shares. | text | 441 | sharesItemType | text: <entity> 441 </entity> <entity type> sharesItemType </entity type> <context> Under the Directors’ 1993 Fee Plan, as amended, non-employee directors may elect to receive up to 100 % of their fees and retainer in shares of Snap-on’s common stock. Directors may elect to defer receipt of all or part of these shares. For 2024, 2023 and 2022, issuances under the Directors’ Fee Plan totaled 441 shares, 449 shares and 621 shares, respectively, of which 184 shares, 176 shares and 309 shares, respectively, were deferred. As of 2024 year end, shares reserved for issuance to directors under this plan totaled 194,840 shares. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
Under the Directors’ 1993 Fee Plan, as amended, non-employee directors may elect to receive up to 100 % of their fees and retainer in shares of Snap-on’s common stock. Directors may elect to defer receipt of all or part of these shares. For 2024, 2023 and 2022, issuances under the Directors’ Fee Plan totaled 441 shares, 449 shares and 621 shares, respectively, of which 184 shares, 176 shares and 309 shares, respectively, were deferred. As of 2024 year end, shares reserved for issuance to directors under this plan totaled 194,840 shares. | text | 449 | sharesItemType | text: <entity> 449 </entity> <entity type> sharesItemType </entity type> <context> Under the Directors’ 1993 Fee Plan, as amended, non-employee directors may elect to receive up to 100 % of their fees and retainer in shares of Snap-on’s common stock. Directors may elect to defer receipt of all or part of these shares. For 2024, 2023 and 2022, issuances under the Directors’ Fee Plan totaled 441 shares, 449 shares and 621 shares, respectively, of which 184 shares, 176 shares and 309 shares, respectively, were deferred. As of 2024 year end, shares reserved for issuance to directors under this plan totaled 194,840 shares. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
Under the Directors’ 1993 Fee Plan, as amended, non-employee directors may elect to receive up to 100 % of their fees and retainer in shares of Snap-on’s common stock. Directors may elect to defer receipt of all or part of these shares. For 2024, 2023 and 2022, issuances under the Directors’ Fee Plan totaled 441 shares, 449 shares and 621 shares, respectively, of which 184 shares, 176 shares and 309 shares, respectively, were deferred. As of 2024 year end, shares reserved for issuance to directors under this plan totaled 194,840 shares. | text | 621 | sharesItemType | text: <entity> 621 </entity> <entity type> sharesItemType </entity type> <context> Under the Directors’ 1993 Fee Plan, as amended, non-employee directors may elect to receive up to 100 % of their fees and retainer in shares of Snap-on’s common stock. Directors may elect to defer receipt of all or part of these shares. For 2024, 2023 and 2022, issuances under the Directors’ Fee Plan totaled 441 shares, 449 shares and 621 shares, respectively, of which 184 shares, 176 shares and 309 shares, respectively, were deferred. As of 2024 year end, shares reserved for issuance to directors under this plan totaled 194,840 shares. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
Under the Directors’ 1993 Fee Plan, as amended, non-employee directors may elect to receive up to 100 % of their fees and retainer in shares of Snap-on’s common stock. Directors may elect to defer receipt of all or part of these shares. For 2024, 2023 and 2022, issuances under the Directors’ Fee Plan totaled 441 shares, 449 shares and 621 shares, respectively, of which 184 shares, 176 shares and 309 shares, respectively, were deferred. As of 2024 year end, shares reserved for issuance to directors under this plan totaled 194,840 shares. | text | 194840 | sharesItemType | text: <entity> 194840 </entity> <entity type> sharesItemType </entity type> <context> Under the Directors’ 1993 Fee Plan, as amended, non-employee directors may elect to receive up to 100 % of their fees and retainer in shares of Snap-on’s common stock. Directors may elect to defer receipt of all or part of these shares. For 2024, 2023 and 2022, issuances under the Directors’ Fee Plan totaled 441 shares, 449 shares and 621 shares, respectively, of which 184 shares, 176 shares and 309 shares, respectively, were deferred. As of 2024 year end, shares reserved for issuance to directors under this plan totaled 194,840 shares. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. | text | 21798 | sharesItemType | text: <entity> 21798 </entity> <entity type> sharesItemType </entity type> <context> Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. | text | 27225 | sharesItemType | text: <entity> 27225 </entity> <entity type> sharesItemType </entity type> <context> Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. | text | 18452 | sharesItemType | text: <entity> 18452 </entity> <entity type> sharesItemType </entity type> <context> Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. | text | 529800 | sharesItemType | text: <entity> 529800 </entity> <entity type> sharesItemType </entity type> <context> Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. | text | 0.9 | monetaryItemType | text: <entity> 0.9 </entity> <entity type> monetaryItemType </entity type> <context> Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> Substantially all Snap-on employees in the United States and Canada are eligible to participate in an employee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records compensation expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 21,798 shares, 27,225 shares and 18,452 shares, respectively. As of 2024 year end, 529,800 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 3.5 million. Participants are able to withdraw from the plan at any time prior to the ending date and receive back all contributions made during the plan year. Compensation expense for plan participants was $ 0.9 million in 2024, $ 1.4 million in 2023 and $ 0.2 million in 2022. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. | text | 42687 | sharesItemType | text: <entity> 42687 </entity> <entity type> sharesItemType </entity type> <context> All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. | text | 46510 | sharesItemType | text: <entity> 46510 </entity> <entity type> sharesItemType </entity type> <context> All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. | text | 44937 | sharesItemType | text: <entity> 44937 </entity> <entity type> sharesItemType </entity type> <context> All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. | text | 136049 | sharesItemType | text: <entity> 136049 </entity> <entity type> sharesItemType </entity type> <context> All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. | text | 0.4 | monetaryItemType | text: <entity> 0.4 </entity> <entity type> monetaryItemType </entity type> <context> All franchisees in the United States and Canada are eligible to participate in a franchisee stock purchase plan. The purchase price of the company’s common stock to participants is the lesser of the mean of the high and low prices of the stock on the beginning date (May 15) or ending date (the following May 14) of each plan year. The company records mark-to-market expense when Snap-on’s period-end stock price is greater than the plan purchase price. For 2024, 2023 and 2022, issuances under this plan totaled 42,687 shares, 46,510 shares and 44,937 shares, respectively. As of 2024 year end, 136,049 shares were reserved for issuance under this plan and Snap-on held participant contributions of approximately $ 7.8 million. Participants are able to withdraw from the plan at any time prior to the ending date and generally receive back all contributions made during the plan year. The company recognized mark-to-market expense of $ 1.9 million in 2024, $ 2.5 million in 2023 and $ 0.4 million in 2022. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
Snap-on has undertaken repurchases of Snap-on common stock from time to time to offset dilution created by shares issued for employee and franchisee stock purchase plans, stock awards and other corporate purposes, as well as when the company believes market conditions are favorable. Snap-on repurchased 952,000 shares, 1,126,000 shares and 899,000 shares in 2024, 2023 and 2022, respectively. As of 2024 year end, Snap-on has remaining availability to repurchase up to an additional $ 429.4 million in common stock pursuant to Board authorizations. The purchase of Snap-on common stock is at the company’s discretion, subject to prevailing financial and market conditions. | text | 952000 | sharesItemType | text: <entity> 952000 </entity> <entity type> sharesItemType </entity type> <context> Snap-on has undertaken repurchases of Snap-on common stock from time to time to offset dilution created by shares issued for employee and franchisee stock purchase plans, stock awards and other corporate purposes, as well as when the company believes market conditions are favorable. Snap-on repurchased 952,000 shares, 1,126,000 shares and 899,000 shares in 2024, 2023 and 2022, respectively. As of 2024 year end, Snap-on has remaining availability to repurchase up to an additional $ 429.4 million in common stock pursuant to Board authorizations. The purchase of Snap-on common stock is at the company’s discretion, subject to prevailing financial and market conditions. </context> | us-gaap:TreasuryStockSharesAcquired |
Snap-on has undertaken repurchases of Snap-on common stock from time to time to offset dilution created by shares issued for employee and franchisee stock purchase plans, stock awards and other corporate purposes, as well as when the company believes market conditions are favorable. Snap-on repurchased 952,000 shares, 1,126,000 shares and 899,000 shares in 2024, 2023 and 2022, respectively. As of 2024 year end, Snap-on has remaining availability to repurchase up to an additional $ 429.4 million in common stock pursuant to Board authorizations. The purchase of Snap-on common stock is at the company’s discretion, subject to prevailing financial and market conditions. | text | 1126000 | sharesItemType | text: <entity> 1126000 </entity> <entity type> sharesItemType </entity type> <context> Snap-on has undertaken repurchases of Snap-on common stock from time to time to offset dilution created by shares issued for employee and franchisee stock purchase plans, stock awards and other corporate purposes, as well as when the company believes market conditions are favorable. Snap-on repurchased 952,000 shares, 1,126,000 shares and 899,000 shares in 2024, 2023 and 2022, respectively. As of 2024 year end, Snap-on has remaining availability to repurchase up to an additional $ 429.4 million in common stock pursuant to Board authorizations. The purchase of Snap-on common stock is at the company’s discretion, subject to prevailing financial and market conditions. </context> | us-gaap:TreasuryStockSharesAcquired |
Snap-on has undertaken repurchases of Snap-on common stock from time to time to offset dilution created by shares issued for employee and franchisee stock purchase plans, stock awards and other corporate purposes, as well as when the company believes market conditions are favorable. Snap-on repurchased 952,000 shares, 1,126,000 shares and 899,000 shares in 2024, 2023 and 2022, respectively. As of 2024 year end, Snap-on has remaining availability to repurchase up to an additional $ 429.4 million in common stock pursuant to Board authorizations. The purchase of Snap-on common stock is at the company’s discretion, subject to prevailing financial and market conditions. | text | 899000 | sharesItemType | text: <entity> 899000 </entity> <entity type> sharesItemType </entity type> <context> Snap-on has undertaken repurchases of Snap-on common stock from time to time to offset dilution created by shares issued for employee and franchisee stock purchase plans, stock awards and other corporate purposes, as well as when the company believes market conditions are favorable. Snap-on repurchased 952,000 shares, 1,126,000 shares and 899,000 shares in 2024, 2023 and 2022, respectively. As of 2024 year end, Snap-on has remaining availability to repurchase up to an additional $ 429.4 million in common stock pursuant to Board authorizations. The purchase of Snap-on common stock is at the company’s discretion, subject to prevailing financial and market conditions. </context> | us-gaap:TreasuryStockSharesAcquired |
Snap-on has undertaken repurchases of Snap-on common stock from time to time to offset dilution created by shares issued for employee and franchisee stock purchase plans, stock awards and other corporate purposes, as well as when the company believes market conditions are favorable. Snap-on repurchased 952,000 shares, 1,126,000 shares and 899,000 shares in 2024, 2023 and 2022, respectively. As of 2024 year end, Snap-on has remaining availability to repurchase up to an additional $ 429.4 million in common stock pursuant to Board authorizations. The purchase of Snap-on common stock is at the company’s discretion, subject to prevailing financial and market conditions. | text | 429.4 | monetaryItemType | text: <entity> 429.4 </entity> <entity type> monetaryItemType </entity type> <context> Snap-on has undertaken repurchases of Snap-on common stock from time to time to offset dilution created by shares issued for employee and franchisee stock purchase plans, stock awards and other corporate purposes, as well as when the company believes market conditions are favorable. Snap-on repurchased 952,000 shares, 1,126,000 shares and 899,000 shares in 2024, 2023 and 2022, respectively. As of 2024 year end, Snap-on has remaining availability to repurchase up to an additional $ 429.4 million in common stock pursuant to Board authorizations. The purchase of Snap-on common stock is at the company’s discretion, subject to prevailing financial and market conditions. </context> | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o | text | 406.4 | monetaryItemType | text: <entity> 406.4 </entity> <entity type> monetaryItemType </entity type> <context> Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o </context> | us-gaap:DividendsCommonStockCash |
Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o | text | 355.6 | monetaryItemType | text: <entity> 355.6 </entity> <entity type> monetaryItemType </entity type> <context> Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o </context> | us-gaap:DividendsCommonStockCash |
Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o | text | 313.1 | monetaryItemType | text: <entity> 313.1 </entity> <entity type> monetaryItemType </entity type> <context> Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o </context> | us-gaap:DividendsCommonStockCash |
Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o | text | 7.72 | perShareItemType | text: <entity> 7.72 </entity> <entity type> perShareItemType </entity type> <context> Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o </context> | us-gaap:CommonStockDividendsPerShareCashPaid |
Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o | text | 6.72 | perShareItemType | text: <entity> 6.72 </entity> <entity type> perShareItemType </entity type> <context> Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o </context> | us-gaap:CommonStockDividendsPerShareCashPaid |
Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o | text | 5.88 | perShareItemType | text: <entity> 5.88 </entity> <entity type> perShareItemType </entity type> <context> Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o </context> | us-gaap:CommonStockDividendsPerShareCashPaid |
Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o | text | 2.14 | perShareItemType | text: <entity> 2.14 </entity> <entity type> perShareItemType </entity type> <context> Cash dividends paid in 2024, 2023 and 2022 totaled $ 406.4 million, $ 355.6 million and $ 313.1 million, respectively. Cash dividends per share in 2024, 2023 and 2022 were $ 7.72 , $ 6.72 and $ 5.88 , respectively. On February 13, 2025, the company’s Board declared a quarterly dividend of $ 2.14 per share, payable o </context> | us-gaap:DividendsPayableAmountPerShare |
In the ordinary course of business, Snap-on is subject to legal disputes that are being litigated and/or settled. The accompanying Consolidated Statements of Earnings for the year ended December 28, 2024, include benefits in “Operating expenses” of $ 22.5 million for payments received associated with a legal matter; the final payments related to this matter were received in the three months ended June 29, 2024. Although it is not possible to predict the outcome of legal matters, management believes that the results of all legal matters will not have a material impact on Snap-on’s consolidated financial position, results of operations or cash flows. | text | 22.5 | monetaryItemType | text: <entity> 22.5 </entity> <entity type> monetaryItemType </entity type> <context> In the ordinary course of business, Snap-on is subject to legal disputes that are being litigated and/or settled. The accompanying Consolidated Statements of Earnings for the year ended December 28, 2024, include benefits in “Operating expenses” of $ 22.5 million for payments received associated with a legal matter; the final payments related to this matter were received in the three months ended June 29, 2024. Although it is not possible to predict the outcome of legal matters, management believes that the results of all legal matters will not have a material impact on Snap-on’s consolidated financial position, results of operations or cash flows. </context> | us-gaap:ProceedsFromLegalSettlements |
Sales-type leases are included in both “Finance receivables – net” and “Long-term finance receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to five years . In 2024 and 2023, finance receivables have future minimum lease payments, including unguaranteed residual value, of $ 53.4 million and $ 28.6 million, respectively, and unearned finance charges of $ 12.2 million and $ 6.2 million, respectively. | text | 53.4 | monetaryItemType | text: <entity> 53.4 </entity> <entity type> monetaryItemType </entity type> <context> Sales-type leases are included in both “Finance receivables – net” and “Long-term finance receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to five years . In 2024 and 2023, finance receivables have future minimum lease payments, including unguaranteed residual value, of $ 53.4 million and $ 28.6 million, respectively, and unearned finance charges of $ 12.2 million and $ 6.2 million, respectively. </context> | us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived |
Sales-type leases are included in both “Finance receivables – net” and “Long-term finance receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to five years . In 2024 and 2023, finance receivables have future minimum lease payments, including unguaranteed residual value, of $ 53.4 million and $ 28.6 million, respectively, and unearned finance charges of $ 12.2 million and $ 6.2 million, respectively. | text | 28.6 | monetaryItemType | text: <entity> 28.6 </entity> <entity type> monetaryItemType </entity type> <context> Sales-type leases are included in both “Finance receivables – net” and “Long-term finance receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to five years . In 2024 and 2023, finance receivables have future minimum lease payments, including unguaranteed residual value, of $ 53.4 million and $ 28.6 million, respectively, and unearned finance charges of $ 12.2 million and $ 6.2 million, respectively. </context> | us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived |
Sales-type leases are included in both “Finance receivables – net” and “Long-term finance receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to five years . In 2024 and 2023, finance receivables have future minimum lease payments, including unguaranteed residual value, of $ 53.4 million and $ 28.6 million, respectively, and unearned finance charges of $ 12.2 million and $ 6.2 million, respectively. | text | 12.2 | monetaryItemType | text: <entity> 12.2 </entity> <entity type> monetaryItemType </entity type> <context> Sales-type leases are included in both “Finance receivables – net” and “Long-term finance receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to five years . In 2024 and 2023, finance receivables have future minimum lease payments, including unguaranteed residual value, of $ 53.4 million and $ 28.6 million, respectively, and unearned finance charges of $ 12.2 million and $ 6.2 million, respectively. </context> | us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount |
Sales-type leases are included in both “Finance receivables – net” and “Long-term finance receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to five years . In 2024 and 2023, finance receivables have future minimum lease payments, including unguaranteed residual value, of $ 53.4 million and $ 28.6 million, respectively, and unearned finance charges of $ 12.2 million and $ 6.2 million, respectively. | text | 6.2 | monetaryItemType | text: <entity> 6.2 </entity> <entity type> monetaryItemType </entity type> <context> Sales-type leases are included in both “Finance receivables – net” and “Long-term finance receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to five years . In 2024 and 2023, finance receivables have future minimum lease payments, including unguaranteed residual value, of $ 53.4 million and $ 28.6 million, respectively, and unearned finance charges of $ 12.2 million and $ 6.2 million, respectively. </context> | us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount |
Sales-type leases are also included in both “Contract receivables – net” and “Long-term contract receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to seven years . In 2024 and 2023, contract receivables have future minimum lease payments, including unguaranteed residual value, of $ 318.6 million and $ 315.7 million, respectively, and unearned finance charges of $ 58.2 million and $ 56.2 million, respectively. | text | 318.6 | monetaryItemType | text: <entity> 318.6 </entity> <entity type> monetaryItemType </entity type> <context> Sales-type leases are also included in both “Contract receivables – net” and “Long-term contract receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to seven years . In 2024 and 2023, contract receivables have future minimum lease payments, including unguaranteed residual value, of $ 318.6 million and $ 315.7 million, respectively, and unearned finance charges of $ 58.2 million and $ 56.2 million, respectively. </context> | us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived |
Sales-type leases are also included in both “Contract receivables – net” and “Long-term contract receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to seven years . In 2024 and 2023, contract receivables have future minimum lease payments, including unguaranteed residual value, of $ 318.6 million and $ 315.7 million, respectively, and unearned finance charges of $ 58.2 million and $ 56.2 million, respectively. | text | 315.7 | monetaryItemType | text: <entity> 315.7 </entity> <entity type> monetaryItemType </entity type> <context> Sales-type leases are also included in both “Contract receivables – net” and “Long-term contract receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to seven years . In 2024 and 2023, contract receivables have future minimum lease payments, including unguaranteed residual value, of $ 318.6 million and $ 315.7 million, respectively, and unearned finance charges of $ 58.2 million and $ 56.2 million, respectively. </context> | us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived |
Sales-type leases are also included in both “Contract receivables – net” and “Long-term contract receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to seven years . In 2024 and 2023, contract receivables have future minimum lease payments, including unguaranteed residual value, of $ 318.6 million and $ 315.7 million, respectively, and unearned finance charges of $ 58.2 million and $ 56.2 million, respectively. | text | 58.2 | monetaryItemType | text: <entity> 58.2 </entity> <entity type> monetaryItemType </entity type> <context> Sales-type leases are also included in both “Contract receivables – net” and “Long-term contract receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to seven years . In 2024 and 2023, contract receivables have future minimum lease payments, including unguaranteed residual value, of $ 318.6 million and $ 315.7 million, respectively, and unearned finance charges of $ 58.2 million and $ 56.2 million, respectively. </context> | us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount |
Sales-type leases are also included in both “Contract receivables – net” and “Long-term contract receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to seven years . In 2024 and 2023, contract receivables have future minimum lease payments, including unguaranteed residual value, of $ 318.6 million and $ 315.7 million, respectively, and unearned finance charges of $ 58.2 million and $ 56.2 million, respectively. | text | 56.2 | monetaryItemType | text: <entity> 56.2 </entity> <entity type> monetaryItemType </entity type> <context> Sales-type leases are also included in both “Contract receivables – net” and “Long-term contract receivables – net” on the accompanying Consolidated Balance Sheets, with lease terms of up to seven years . In 2024 and 2023, contract receivables have future minimum lease payments, including unguaranteed residual value, of $ 318.6 million and $ 315.7 million, respectively, and unearned finance charges of $ 58.2 million and $ 56.2 million, respectively. </context> | us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount |
(crinecerfont) in the U.S. to a specialty pharmacy provider. Net product sales of INGREZZA totaled $ 2.3 billion for 2024, $ 1.8 billion for 2023, and $ 1.4 billion for 2022 and accounted for substantially all of our total net product sales during each of these years. | text | 2.3 | monetaryItemType | text: <entity> 2.3 </entity> <entity type> monetaryItemType </entity type> <context> (crinecerfont) in the U.S. to a specialty pharmacy provider. Net product sales of INGREZZA totaled $ 2.3 billion for 2024, $ 1.8 billion for 2023, and $ 1.4 billion for 2022 and accounted for substantially all of our total net product sales during each of these years. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
(crinecerfont) in the U.S. to a specialty pharmacy provider. Net product sales of INGREZZA totaled $ 2.3 billion for 2024, $ 1.8 billion for 2023, and $ 1.4 billion for 2022 and accounted for substantially all of our total net product sales during each of these years. | text | 1.8 | monetaryItemType | text: <entity> 1.8 </entity> <entity type> monetaryItemType </entity type> <context> (crinecerfont) in the U.S. to a specialty pharmacy provider. Net product sales of INGREZZA totaled $ 2.3 billion for 2024, $ 1.8 billion for 2023, and $ 1.4 billion for 2022 and accounted for substantially all of our total net product sales during each of these years. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
(crinecerfont) in the U.S. to a specialty pharmacy provider. Net product sales of INGREZZA totaled $ 2.3 billion for 2024, $ 1.8 billion for 2023, and $ 1.4 billion for 2022 and accounted for substantially all of our total net product sales during each of these years. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> (crinecerfont) in the U.S. to a specialty pharmacy provider. Net product sales of INGREZZA totaled $ 2.3 billion for 2024, $ 1.8 billion for 2023, and $ 1.4 billion for 2022 and accounted for substantially all of our total net product sales during each of these years. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
Accrued interest receivables on available-for-sale debt securities were $ 14.4 million and $ 11.2 million, respectively, as of December 31, 2024 and 2023. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2024, 2023, or 2022. | text | 14.4 | monetaryItemType | text: <entity> 14.4 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivables on available-for-sale debt securities were $ 14.4 million and $ 11.2 million, respectively, as of December 31, 2024 and 2023. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2024, 2023, or 2022. </context> | us-gaap:InterestReceivableCurrent |
Accrued interest receivables on available-for-sale debt securities were $ 14.4 million and $ 11.2 million, respectively, as of December 31, 2024 and 2023. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2024, 2023, or 2022. | text | 11.2 | monetaryItemType | text: <entity> 11.2 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivables on available-for-sale debt securities were $ 14.4 million and $ 11.2 million, respectively, as of December 31, 2024 and 2023. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2024, 2023, or 2022. </context> | us-gaap:InterestReceivableCurrent |
Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $ 23.5 million for 2024, $ 17.8 million for 2023, and $ 15.1 million for 2022. | text | 23.5 | monetaryItemType | text: <entity> 23.5 </entity> <entity type> monetaryItemType </entity type> <context> Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $ 23.5 million for 2024, $ 17.8 million for 2023, and $ 15.1 million for 2022. </context> | us-gaap:Depreciation |
Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $ 23.5 million for 2024, $ 17.8 million for 2023, and $ 15.1 million for 2022. | text | 17.8 | monetaryItemType | text: <entity> 17.8 </entity> <entity type> monetaryItemType </entity type> <context> Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $ 23.5 million for 2024, $ 17.8 million for 2023, and $ 15.1 million for 2022. </context> | us-gaap:Depreciation |
Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $ 23.5 million for 2024, $ 17.8 million for 2023, and $ 15.1 million for 2022. | text | 15.1 | monetaryItemType | text: <entity> 15.1 </entity> <entity type> monetaryItemType </entity type> <context> Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $ 23.5 million for 2024, $ 17.8 million for 2023, and $ 15.1 million for 2022. </context> | us-gaap:Depreciation |
Costs associated with advertising are expensed as incurred and are included in selling, general, and administrative on the consolidated statements of income. Advertising expenses were $ 191.0 million for 2024, $ 159.9 million for 2023, and $ 149.7 million for 2022. | text | 191.0 | monetaryItemType | text: <entity> 191.0 </entity> <entity type> monetaryItemType </entity type> <context> Costs associated with advertising are expensed as incurred and are included in selling, general, and administrative on the consolidated statements of income. Advertising expenses were $ 191.0 million for 2024, $ 159.9 million for 2023, and $ 149.7 million for 2022. </context> | us-gaap:AdvertisingExpense |
Costs associated with advertising are expensed as incurred and are included in selling, general, and administrative on the consolidated statements of income. Advertising expenses were $ 191.0 million for 2024, $ 159.9 million for 2023, and $ 149.7 million for 2022. | text | 159.9 | monetaryItemType | text: <entity> 159.9 </entity> <entity type> monetaryItemType </entity type> <context> Costs associated with advertising are expensed as incurred and are included in selling, general, and administrative on the consolidated statements of income. Advertising expenses were $ 191.0 million for 2024, $ 159.9 million for 2023, and $ 149.7 million for 2022. </context> | us-gaap:AdvertisingExpense |
Costs associated with advertising are expensed as incurred and are included in selling, general, and administrative on the consolidated statements of income. Advertising expenses were $ 191.0 million for 2024, $ 159.9 million for 2023, and $ 149.7 million for 2022. | text | 149.7 | monetaryItemType | text: <entity> 149.7 </entity> <entity type> monetaryItemType </entity type> <context> Costs associated with advertising are expensed as incurred and are included in selling, general, and administrative on the consolidated statements of income. Advertising expenses were $ 191.0 million for 2024, $ 159.9 million for 2023, and $ 149.7 million for 2022. </context> | us-gaap:AdvertisingExpense |
In connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in 2022, we expensed a milestone payment of $ 30.0 million to Nxera as R&D in 2022. | text | 30.0 | monetaryItemType | text: <entity> 30.0 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in 2022, we expensed a milestone payment of $ 30.0 million to Nxera as R&D in 2022. </context> | us-gaap:ResearchAndDevelopmentExpense |
In connection with the successful completions of a long-term toxicity program for NBI-1117568 and a Phase 2 clinical study for NBI-1117568 in schizophrenia in 2024, we expensed milestone payments totaling $ 50.0 million to Nxera as R&D in 2024. We expect to advance NBI-1117568 into Phase 3 development in the first half of 2025, which would trigger a milestone of $ 15.0 million payable to Nxera upon initiation of the Phase 3 clinical study. | text | 50.0 | monetaryItemType | text: <entity> 50.0 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the successful completions of a long-term toxicity program for NBI-1117568 and a Phase 2 clinical study for NBI-1117568 in schizophrenia in 2024, we expensed milestone payments totaling $ 50.0 million to Nxera as R&D in 2024. We expect to advance NBI-1117568 into Phase 3 development in the first half of 2025, which would trigger a milestone of $ 15.0 million payable to Nxera upon initiation of the Phase 3 clinical study. </context> | us-gaap:ResearchAndDevelopmentExpense |
In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in 2022, we expensed a milestone payment of $ 5.0 million to Takeda as R&D in 2022. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in 2022, we expensed a milestone payment of $ 5.0 million to Takeda as R&D in 2022. </context> | us-gaap:ResearchAndDevelopmentExpense |
In connection with the initiation of a Phase 2 clinical study for NBI-1070770 in major depressive disorder in 2024, we expensed a milestone payment of $ 7.5 million to Takeda as R&D in 2024. | text | 7.5 | monetaryItemType | text: <entity> 7.5 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the initiation of a Phase 2 clinical study for NBI-1070770 in major depressive disorder in 2024, we expensed a milestone payment of $ 7.5 million to Takeda as R&D in 2024. </context> | us-gaap:ResearchAndDevelopmentExpense |
In connection with the achievement of a development milestone in 2022, we paid Xenon $ 15.0 million, including a purchase of 0.3 million shares (at $ 31.855 per share) of Xenon common stock (the 2022 Xenon Shares). The 2022 Xenon Shares were recorded at a fair value of $ 7.7 million after considering Xenon’s stock price on the measurement date. The remaining $ 7.3 million of the milestone payment was expensed as R&D in 2022. | text | 31.855 | perShareItemType | text: <entity> 31.855 </entity> <entity type> perShareItemType </entity type> <context> In connection with the achievement of a development milestone in 2022, we paid Xenon $ 15.0 million, including a purchase of 0.3 million shares (at $ 31.855 per share) of Xenon common stock (the 2022 Xenon Shares). The 2022 Xenon Shares were recorded at a fair value of $ 7.7 million after considering Xenon’s stock price on the measurement date. The remaining $ 7.3 million of the milestone payment was expensed as R&D in 2022. </context> | us-gaap:SharePrice |
In connection with the achievement of a development milestone in 2022, we paid Xenon $ 15.0 million, including a purchase of 0.3 million shares (at $ 31.855 per share) of Xenon common stock (the 2022 Xenon Shares). The 2022 Xenon Shares were recorded at a fair value of $ 7.7 million after considering Xenon’s stock price on the measurement date. The remaining $ 7.3 million of the milestone payment was expensed as R&D in 2022. | text | 7.7 | monetaryItemType | text: <entity> 7.7 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the achievement of a development milestone in 2022, we paid Xenon $ 15.0 million, including a purchase of 0.3 million shares (at $ 31.855 per share) of Xenon common stock (the 2022 Xenon Shares). The 2022 Xenon Shares were recorded at a fair value of $ 7.7 million after considering Xenon’s stock price on the measurement date. The remaining $ 7.3 million of the milestone payment was expensed as R&D in 2022. </context> | us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue |
In connection with the achievement of a development milestone in 2022, we paid Xenon $ 15.0 million, including a purchase of 0.3 million shares (at $ 31.855 per share) of Xenon common stock (the 2022 Xenon Shares). The 2022 Xenon Shares were recorded at a fair value of $ 7.7 million after considering Xenon’s stock price on the measurement date. The remaining $ 7.3 million of the milestone payment was expensed as R&D in 2022. | text | 7.3 | monetaryItemType | text: <entity> 7.3 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the achievement of a development milestone in 2022, we paid Xenon $ 15.0 million, including a purchase of 0.3 million shares (at $ 31.855 per share) of Xenon common stock (the 2022 Xenon Shares). The 2022 Xenon Shares were recorded at a fair value of $ 7.7 million after considering Xenon’s stock price on the measurement date. The remaining $ 7.3 million of the milestone payment was expensed as R&D in 2022. </context> | us-gaap:ResearchAndDevelopmentExpense |
In connection with the 2019 Voyager Agreement, we purchased 4.2 million shares (at $ 11.9625 per share) of Voyager common stock (the 2019 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement (defined below). The 2019 Voyager Shares were recorded at a fair value of $ 54.7 million after considering Voyager’s stock price and certain transfer restrictions that were applicable to the shares on the measurement date. | text | 11.9625 | perShareItemType | text: <entity> 11.9625 </entity> <entity type> perShareItemType </entity type> <context> In connection with the 2019 Voyager Agreement, we purchased 4.2 million shares (at $ 11.9625 per share) of Voyager common stock (the 2019 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement (defined below). The 2019 Voyager Shares were recorded at a fair value of $ 54.7 million after considering Voyager’s stock price and certain transfer restrictions that were applicable to the shares on the measurement date. </context> | us-gaap:SharePrice |
In connection with the 2019 Voyager Agreement, we purchased 4.2 million shares (at $ 11.9625 per share) of Voyager common stock (the 2019 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement (defined below). The 2019 Voyager Shares were recorded at a fair value of $ 54.7 million after considering Voyager’s stock price and certain transfer restrictions that were applicable to the shares on the measurement date. | text | 54.7 | monetaryItemType | text: <entity> 54.7 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the 2019 Voyager Agreement, we purchased 4.2 million shares (at $ 11.9625 per share) of Voyager common stock (the 2019 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement (defined below). The 2019 Voyager Shares were recorded at a fair value of $ 54.7 million after considering Voyager’s stock price and certain transfer restrictions that were applicable to the shares on the measurement date. </context> | us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue |
In connection with the selection of a development candidate under the FA program pursuant to our collaboration with Voyager, we expensed a milestone payment of $ 5.0 million to Voyager as R&D in 2024. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the selection of a development candidate under the FA program pursuant to our collaboration with Voyager, we expensed a milestone payment of $ 5.0 million to Voyager as R&D in 2024. </context> | us-gaap:ResearchAndDevelopmentExpense |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. In addition, as part of the collaboration, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine Biosciences, was appointed to Voyager's board of directors. Dr. Onyia (or another individual designated by us) will be nominated for election to Voyager's board of directors annually for a maximum duration of 10 years from the effective date of the 2023 Voyager Agreement. As a result, our equity investment in Voyager became subject to the equity method of accounting, and Voyager became a related party, following our purchase of the 2023 Voyager Shares, after which, together with the 2019 Voyager Shares, we owned approximately 19.9 % of the voting stock of Voyager. We elected the fair value option to account for our equity investment in Voyager as we believe it creates greater transparency regarding the investment's fair value at future reporting dates. The 2023 Voyager Shares were recorded at a fair value of $ 31.3 million after considering Voyager’s stock price on the measurement date. The remaining $ 143.9 million of the purchase price, which includes certain transaction-related costs, was expensed as in-process research and development in the first quarter of 2023 as the license had no foreseeable alternative future use. | text | 8.88 | perShareItemType | text: <entity> 8.88 </entity> <entity type> perShareItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. In addition, as part of the collaboration, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine Biosciences, was appointed to Voyager's board of directors. Dr. Onyia (or another individual designated by us) will be nominated for election to Voyager's board of directors annually for a maximum duration of 10 years from the effective date of the 2023 Voyager Agreement. As a result, our equity investment in Voyager became subject to the equity method of accounting, and Voyager became a related party, following our purchase of the 2023 Voyager Shares, after which, together with the 2019 Voyager Shares, we owned approximately 19.9 % of the voting stock of Voyager. We elected the fair value option to account for our equity investment in Voyager as we believe it creates greater transparency regarding the investment's fair value at future reporting dates. The 2023 Voyager Shares were recorded at a fair value of $ 31.3 million after considering Voyager’s stock price on the measurement date. The remaining $ 143.9 million of the purchase price, which includes certain transaction-related costs, was expensed as in-process research and development in the first quarter of 2023 as the license had no foreseeable alternative future use. </context> | us-gaap:SharePrice |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. In addition, as part of the collaboration, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine Biosciences, was appointed to Voyager's board of directors. Dr. Onyia (or another individual designated by us) will be nominated for election to Voyager's board of directors annually for a maximum duration of 10 years from the effective date of the 2023 Voyager Agreement. As a result, our equity investment in Voyager became subject to the equity method of accounting, and Voyager became a related party, following our purchase of the 2023 Voyager Shares, after which, together with the 2019 Voyager Shares, we owned approximately 19.9 % of the voting stock of Voyager. We elected the fair value option to account for our equity investment in Voyager as we believe it creates greater transparency regarding the investment's fair value at future reporting dates. The 2023 Voyager Shares were recorded at a fair value of $ 31.3 million after considering Voyager’s stock price on the measurement date. The remaining $ 143.9 million of the purchase price, which includes certain transaction-related costs, was expensed as in-process research and development in the first quarter of 2023 as the license had no foreseeable alternative future use. | text | 19.9 | percentItemType | text: <entity> 19.9 </entity> <entity type> percentItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. In addition, as part of the collaboration, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine Biosciences, was appointed to Voyager's board of directors. Dr. Onyia (or another individual designated by us) will be nominated for election to Voyager's board of directors annually for a maximum duration of 10 years from the effective date of the 2023 Voyager Agreement. As a result, our equity investment in Voyager became subject to the equity method of accounting, and Voyager became a related party, following our purchase of the 2023 Voyager Shares, after which, together with the 2019 Voyager Shares, we owned approximately 19.9 % of the voting stock of Voyager. We elected the fair value option to account for our equity investment in Voyager as we believe it creates greater transparency regarding the investment's fair value at future reporting dates. The 2023 Voyager Shares were recorded at a fair value of $ 31.3 million after considering Voyager’s stock price on the measurement date. The remaining $ 143.9 million of the purchase price, which includes certain transaction-related costs, was expensed as in-process research and development in the first quarter of 2023 as the license had no foreseeable alternative future use. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. In addition, as part of the collaboration, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine Biosciences, was appointed to Voyager's board of directors. Dr. Onyia (or another individual designated by us) will be nominated for election to Voyager's board of directors annually for a maximum duration of 10 years from the effective date of the 2023 Voyager Agreement. As a result, our equity investment in Voyager became subject to the equity method of accounting, and Voyager became a related party, following our purchase of the 2023 Voyager Shares, after which, together with the 2019 Voyager Shares, we owned approximately 19.9 % of the voting stock of Voyager. We elected the fair value option to account for our equity investment in Voyager as we believe it creates greater transparency regarding the investment's fair value at future reporting dates. The 2023 Voyager Shares were recorded at a fair value of $ 31.3 million after considering Voyager’s stock price on the measurement date. The remaining $ 143.9 million of the purchase price, which includes certain transaction-related costs, was expensed as in-process research and development in the first quarter of 2023 as the license had no foreseeable alternative future use. | text | 31.3 | monetaryItemType | text: <entity> 31.3 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. In addition, as part of the collaboration, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine Biosciences, was appointed to Voyager's board of directors. Dr. Onyia (or another individual designated by us) will be nominated for election to Voyager's board of directors annually for a maximum duration of 10 years from the effective date of the 2023 Voyager Agreement. As a result, our equity investment in Voyager became subject to the equity method of accounting, and Voyager became a related party, following our purchase of the 2023 Voyager Shares, after which, together with the 2019 Voyager Shares, we owned approximately 19.9 % of the voting stock of Voyager. We elected the fair value option to account for our equity investment in Voyager as we believe it creates greater transparency regarding the investment's fair value at future reporting dates. The 2023 Voyager Shares were recorded at a fair value of $ 31.3 million after considering Voyager’s stock price on the measurement date. The remaining $ 143.9 million of the purchase price, which includes certain transaction-related costs, was expensed as in-process research and development in the first quarter of 2023 as the license had no foreseeable alternative future use. </context> | us-gaap:EquitySecuritiesFvNiCost |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. In addition, as part of the collaboration, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine Biosciences, was appointed to Voyager's board of directors. Dr. Onyia (or another individual designated by us) will be nominated for election to Voyager's board of directors annually for a maximum duration of 10 years from the effective date of the 2023 Voyager Agreement. As a result, our equity investment in Voyager became subject to the equity method of accounting, and Voyager became a related party, following our purchase of the 2023 Voyager Shares, after which, together with the 2019 Voyager Shares, we owned approximately 19.9 % of the voting stock of Voyager. We elected the fair value option to account for our equity investment in Voyager as we believe it creates greater transparency regarding the investment's fair value at future reporting dates. The 2023 Voyager Shares were recorded at a fair value of $ 31.3 million after considering Voyager’s stock price on the measurement date. The remaining $ 143.9 million of the purchase price, which includes certain transaction-related costs, was expensed as in-process research and development in the first quarter of 2023 as the license had no foreseeable alternative future use. | text | 143.9 | monetaryItemType | text: <entity> 143.9 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Voyager Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. In addition, as part of the collaboration, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine Biosciences, was appointed to Voyager's board of directors. Dr. Onyia (or another individual designated by us) will be nominated for election to Voyager's board of directors annually for a maximum duration of 10 years from the effective date of the 2023 Voyager Agreement. As a result, our equity investment in Voyager became subject to the equity method of accounting, and Voyager became a related party, following our purchase of the 2023 Voyager Shares, after which, together with the 2019 Voyager Shares, we owned approximately 19.9 % of the voting stock of Voyager. We elected the fair value option to account for our equity investment in Voyager as we believe it creates greater transparency regarding the investment's fair value at future reporting dates. The 2023 Voyager Shares were recorded at a fair value of $ 31.3 million after considering Voyager’s stock price on the measurement date. The remaining $ 143.9 million of the purchase price, which includes certain transaction-related costs, was expensed as in-process research and development in the first quarter of 2023 as the license had no foreseeable alternative future use. </context> | us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff |
In connection with the selection of two development candidates under the GBA1 program pursuant to our collaboration with Voyager, we expensed milestone payments totaling $ 6.0 million to Voyager as R&D in 2024. | text | 6.0 | monetaryItemType | text: <entity> 6.0 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the selection of two development candidates under the GBA1 program pursuant to our collaboration with Voyager, we expensed milestone payments totaling $ 6.0 million to Voyager as R&D in 2024. </context> | us-gaap:ResearchAndDevelopmentExpense |
In connection with FDA approval of CRENESSITY capsules and oral solution as an adjunctive treatment of classic congenital adrenal hyperplasia (CAH) in December 2024, we paid a $ 5.0 million milestone to Sanofi in January 2025, which we accrued to other current liabilities and recorded within intangible assets, net on the consolidated balance sheet as of December 31, 2024. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> In connection with FDA approval of CRENESSITY capsules and oral solution as an adjunctive treatment of classic congenital adrenal hyperplasia (CAH) in December 2024, we paid a $ 5.0 million milestone to Sanofi in January 2025, which we accrued to other current liabilities and recorded within intangible assets, net on the consolidated balance sheet as of December 31, 2024. </context> | us-gaap:ResearchAndDevelopmentExpense |
In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $ 20.0 million in 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC’s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in 2022. | text | 20.0 | monetaryItemType | text: <entity> 20.0 </entity> <entity type> monetaryItemType </entity type> <context> In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $ 20.0 million in 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC’s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in 2022. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $ 13.5 million for 2024, $ 16.7 million for 2023, and $ 21.2 million for 2022. | text | 13.5 | monetaryItemType | text: <entity> 13.5 </entity> <entity type> monetaryItemType </entity type> <context> (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $ 13.5 million for 2024, $ 16.7 million for 2023, and $ 21.2 million for 2022. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $ 13.5 million for 2024, $ 16.7 million for 2023, and $ 21.2 million for 2022. | text | 16.7 | monetaryItemType | text: <entity> 16.7 </entity> <entity type> monetaryItemType </entity type> <context> (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $ 13.5 million for 2024, $ 16.7 million for 2023, and $ 21.2 million for 2022. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $ 13.5 million for 2024, $ 16.7 million for 2023, and $ 21.2 million for 2022. | text | 21.2 | monetaryItemType | text: <entity> 21.2 </entity> <entity type> monetaryItemType </entity type> <context> (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $ 13.5 million for 2024, $ 16.7 million for 2023, and $ 21.2 million for 2022. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 2.4 million for 2024, 4.7 million for 2023, and 4.6 million for 2022. | text | 2.4 | sharesItemType | text: <entity> 2.4 </entity> <entity type> sharesItemType </entity type> <context> Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 2.4 million for 2024, 4.7 million for 2023, and 4.6 million for 2022. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 2.4 million for 2024, 4.7 million for 2023, and 4.6 million for 2022. | text | 4.7 | sharesItemType | text: <entity> 4.7 </entity> <entity type> sharesItemType </entity type> <context> Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 2.4 million for 2024, 4.7 million for 2023, and 4.6 million for 2022. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 2.4 million for 2024, 4.7 million for 2023, and 4.6 million for 2022. | text | 4.6 | sharesItemType | text: <entity> 4.6 </entity> <entity type> sharesItemType </entity type> <context> Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 2.4 million for 2024, 4.7 million for 2023, and 4.6 million for 2022. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
At inception, we paid the financial institution $ 300.0 million using cash on hand and took initial delivery of 2.0 million shares, which resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares for both basic and diluted earnings per share. The fair market value of the 2.0 million initial shares received was $ 240.5 million, with the par value of the initial shares received recorded as a reduction to common stock, the excess of the fair market value over the par value of the initial shares received recorded as a reduction to retained earnings to the extent available, and the remainder recorded as a reduction to additional paid-in capital. The remaining $ 59.5 million of the repurchase price was recorded to additional paid-in capital. | text | 300.0 | monetaryItemType | text: <entity> 300.0 </entity> <entity type> monetaryItemType </entity type> <context> At inception, we paid the financial institution $ 300.0 million using cash on hand and took initial delivery of 2.0 million shares, which resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares for both basic and diluted earnings per share. The fair market value of the 2.0 million initial shares received was $ 240.5 million, with the par value of the initial shares received recorded as a reduction to common stock, the excess of the fair market value over the par value of the initial shares received recorded as a reduction to retained earnings to the extent available, and the remainder recorded as a reduction to additional paid-in capital. The remaining $ 59.5 million of the repurchase price was recorded to additional paid-in capital. </context> | us-gaap:PaymentsForRepurchaseOfCommonStock |
At inception, we paid the financial institution $ 300.0 million using cash on hand and took initial delivery of 2.0 million shares, which resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares for both basic and diluted earnings per share. The fair market value of the 2.0 million initial shares received was $ 240.5 million, with the par value of the initial shares received recorded as a reduction to common stock, the excess of the fair market value over the par value of the initial shares received recorded as a reduction to retained earnings to the extent available, and the remainder recorded as a reduction to additional paid-in capital. The remaining $ 59.5 million of the repurchase price was recorded to additional paid-in capital. | text | 2.0 | sharesItemType | text: <entity> 2.0 </entity> <entity type> sharesItemType </entity type> <context> At inception, we paid the financial institution $ 300.0 million using cash on hand and took initial delivery of 2.0 million shares, which resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares for both basic and diluted earnings per share. The fair market value of the 2.0 million initial shares received was $ 240.5 million, with the par value of the initial shares received recorded as a reduction to common stock, the excess of the fair market value over the par value of the initial shares received recorded as a reduction to retained earnings to the extent available, and the remainder recorded as a reduction to additional paid-in capital. The remaining $ 59.5 million of the repurchase price was recorded to additional paid-in capital. </context> | us-gaap:StockRepurchasedDuringPeriodShares |
The ASR transaction terminated in February 2025, at which time we became contractually entitled to receive an additional 0.3 million shares upon settlement. | text | 0.3 | sharesItemType | text: <entity> 0.3 </entity> <entity type> sharesItemType </entity type> <context> The ASR transaction terminated in February 2025, at which time we became contractually entitled to receive an additional 0.3 million shares upon settlement. </context> | us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue |
In May 2022, 2023, and 2024, our stockholders approved amendments of the 2020 Equity Incentive Plan (as so amended, the Amended 2020 Plan). The Amended 2020 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other awards. As of December 31, 2024, 10.6 million shares of common stock remain available for future grant under the Amended 2020 Plan. | text | 10.6 | sharesItemType | text: <entity> 10.6 </entity> <entity type> sharesItemType </entity type> <context> In May 2022, 2023, and 2024, our stockholders approved amendments of the 2020 Equity Incentive Plan (as so amended, the Amended 2020 Plan). The Amended 2020 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other awards. As of December 31, 2024, 10.6 million shares of common stock remain available for future grant under the Amended 2020 Plan. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
In May 2011, we adopted the 2011 Equity Incentive Plan (the 2011 Plan). The 2011 Plan was a stockholder-approved plan pursuant to which outstanding awards have been made, but from which no further awards can or will be made. | text | no | sharesItemType | text: <entity> no </entity> <entity type> sharesItemType </entity type> <context> In May 2011, we adopted the 2011 Equity Incentive Plan (the 2011 Plan). The 2011 Plan was a stockholder-approved plan pursuant to which outstanding awards have been made, but from which no further awards can or will be made. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.